Dominant-negative Inhibition of Pheromone Receptor Signaling by a Single Point Mutation in the G Protein α Subunit by Wu, Yuh Lin et al.
Dominant-negative Inhibition of Pheromone Receptor Signaling by
a Single Point Mutation in the G Protein  Subunit*
Received for publication, May 3, 2004, and in revised form, June 9, 2004
Published, JBC Papers in Press, June 14, 2004, DOI 10.1074/jbc.M404896200
Yuh-Lin Wu‡, Shelley B. Hooks§, T. Kendall Harden§, and Henrik G. Dohlman‡§¶
From the ‡Department of Biochemistry and Biophysics and the §Department of Pharmacology, University of North
Carolina, Chapel Hill, North Carolina 27599-7260
In yeast, two different constitutive mutants of the G
protein  subunit have been reported. Gpa1Q323L cannot
hydrolyze GTP and permanently activates the phero-
mone response pathway. Gpa1N388D was also proposed
to lack GTPase activity, yet it has an inhibitory effect on
pheromone responsiveness. We have characterized this
inhibitory mutant (designated GND) and found that it
binds GTP, interacts with G protein  subunits, and
exhibits full GTPase activity in vitro. Although phero-
mone leads to dissociation of the receptor from wild-
type G protein, the same treatment promotes stable as-
sociation of the receptor with GND. We conclude that
agonist binding to the receptor promotes the formation
of a nondissociable complex with GND, and in this man-
ner prevents activation of the endogenous wild-type G
protein. Dominant-negative mutants may be useful in
matching specific receptors and their cognate G pro-
teins and in determining mechanisms of G protein sig-
naling specificity.
Mammalian G protein-coupled receptors (GPCRs)1 respond
to a variety of signaling molecules, including hormones, neu-
rotransmitters, odors, and light. These signals regulate diverse
cellular processes, such as the control of blood pressure and
heart rate, perception of pain, cell proliferation, inflammation,
and platelet aggregation (1–3). Upon binding of an agonist to
its cognate receptor, the G protein  subunit transits from a
GDP-bound to a GTP-bound state and liberates the G protein
 subunit complex. The dissociated  (in the GTP-bound state)
and  subunits then activate a variety of downstream effec-
tors. Regulators of G protein signaling reverse this process by
binding to G-GTP and promoting GTP hydrolysis, after which
the subunits reassociate and signaling terminates (4).
A prominent feature of G protein signaling is the tremendous
diversity of the component proteins. Human genome analysis
has revealed genes that encode several hundred candidate
GPCRs, 16  subunits, 5  subunits, and 12  subunits (5).
Further diversity results from alternative mRNA splicing and
the potential of a given receptor to transduce signals to multi-
ple G protein subunit subtypes and effectors. These signaling
components do not assemble randomly; rather, one receptor
typically activates only a subset of G protein heterotrimers,
and the dissociated subunits activate only a subset of down-
stream effectors (5).
Clearly, a major challenge is to define the coupling specificity
of specific receptors, G proteins, and effectors. Bacterial toxins
have long been used to perturb signaling mediated by suscep-
tible G proteins. Cholera toxin catalyzes the ADP-ribosylation
of Gs resulting in inactivation of its GTPase activity, thus
maintaining Gs in the active GTP-bound state. Pertussis toxin
catalyzes ADP-ribosylation of Gi, and this modification blocks
G protein coupling to GPCRs (6). However, pertussis toxin does
not modify all members of the Gi subfamily, and no toxins
have been identified that modify members of the Gq and G12
subfamilies. Thus, more general approaches are needed to an-
alyze receptor and G protein coupling specificity.
An alternative approach to studying G protein signal speci-
ficity has been to mutate residues in G critical for GTPase
activity. One early example of an activated G protein allele was
described by Landis et al. (7), who showed that certain types of
human pituitary tumors are associated with GTPase-deficient
mutants of Gs. Another GTPase-deficient mutant replaces
Gln-204 in Gi (Gln-277 in Gs and Gln-323 in Gpa1) (8–10). A
crystal structure of Gi
Q204L and additional biochemical anal-
ysis suggest that the catalytic Gln acts by stabilizing the trig-
onal-bipyramidal transition state and by helping to orient the
hydrolytic water molecule (11, 12). This mutation is widely
used to identify signaling pathways activated by G subunits,
and we recently used this approach to show that the yeast G
subunit Gpa1 directly activates the mating response pathway,
in conjunction with G (13).
Another approach is to inactivate G protein function by using
mutants that confer a dominant-negative effect on signaling
(14). Dominant-negative mutants are proteins that disrupt the
function of the endogenous wild-type protein when overex-
pressed. Thus, highly specific dominant-negative G proteins
have tremendous potential for ascertaining the signaling spec-
ificity of diverse G proteins in complex systems. Although such
mutants have been reported (15–21) for various G subunits,
they have not yet been proved to be generally applicable to
studying G protein signaling.
In contrast to the large number and variety of mammalian
GPCRs, only two distinct G protein signaling systems exist in
yeast. The first regulates the response to mating pheromones,
which are secreted by haploid a and  cell types in preparation
for mating. Pheromone binding to receptors (e.g. Ste2 in a cells)
triggers dissociation of G (Gpa1) from the G heterodimer
(Ste4/Ste18). The dissociated subunits proceed to activate a
mitogen-activated protein kinase cascade, resulting in new
gene transcription, cell cycle arrest, and eventually cell fusion
to form the a/ diploid (22). The second signaling pathway
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mediates the cellular response to glucose and environmental
stressors such as high osmolarity and heat shock. Components
of this pathway include the G protein Gpa2 working in con-
junction with the putative glucose receptor Gpr1 (23, 24). Re-
cent studies of Gpr1 signaling have identified two candidate G
subunits, Gpb1 and Gpb2, and a candidate G, Gpg1 (25, 26).
The Gpb1/2 proteins lack the seven WD40 repeats found in
classical G proteins, but instead contain seven kelch repeats
implicated in protein-protein interaction (26). The effector for
this G protein has not been positively identified, and generally
speaking much less is known about this pathway.
Two different constitutive mutants in the yeast G subunit
have been described. Gpa1Q323L binds but does not hydrolyze
GTP (13, 27). Gpa1N388D was proposed to lack GTPase activity
but paradoxically has an opposing or inhibitory effect on the
pathway (28–30). We previously characterized the biochemical
and physiological function of Gpa1Q323L (13, 27), and here we
characterize the inhibitory GND mutant. We report that GND
binds and hydrolyzes GTP but is unable to dissociate effectively
from receptors and therefore acts as a potent dominant-nega-
tive inhibitor of receptor signaling.
MATERIALS AND METHODS
Strains, Media, and Plasmids—Established methods were used for
the growth and genetic manipulation of bacteria and yeast (31). Esch-
erichia coli strain DH 5 was used for plasmid maintenance and am-
plification. The strains of yeast Saccharomyces cerevisiae used in this
study are as follows: YPH499 (MATa leu2-1 his3-200 trp1-63 ade2-
101oc lys2-801am ura3-52), YPH501 (YPH499 MATa/) (32), YGS5
(YPH499 gpa1::hisG ste11ts) (33), BY4741 (MATa his31 leu20
met150 ura30; from Research Genetics, Huntsville, AL), and a
BY4741-derived gpa1 ste7 mutant strain (MATa ste7::KanMX
gpa1::hisG, provided by Paul Flanary, University of North Carolina).
Yeast cells were grown in synthetic medium supplemented with
adenine, amino acids, 2% glucose (SCD), or 2% galactose plus 0.2%
sucrose (SCG) to express GAL1/10-inducible genes. Leucine, uracil,
tryptophan, or histidine was omitted to maintain selection of plasmids
as needed. Yeast cells were grown at 30 °C unless otherwise stated. The
absence of GPA1 in strain YGS5 normally results in constitutive G
signaling and growth arrest; however, these cells can be maintained at
34 °C due to inactivation of the temperature-sensitive ste11 mutant.
Several expression plasmids used in this study have been described
previously: pRS315 (CEN, LEU2), pRS423 (2 m, HIS3), pRS424 (2
m, TRP1) (32), pAD4M (2 m, LEU2, ADH1 promoter and termina-
tor), and pAD4M-GST and pAD4M-GPA1-GST (34). pGALH (2 m,
LEU2) and pGALL (2 m, LEU2) contain partially active GAL1/10
promoter sequences having 18–20 (pGALH) or 1% (pGALH) full activity
(35) (provided by Ming Guo, Yale University). pRS315-GPA1 contains
the GPA1 gene under the control of the native promoter.
Wild-type human Gi2 in pcDNA3.1 mammalian expression vector
was obtained from the Guthrie cDNA Resource Center (Sayre, PA). The
N270D mutation was introduced using a QuikChange mutagenesis kit
(Stratagene, Alameda, CA). The mutant was amplified by PCR and
ligated into pFastBacHta (Invitrogen) digested with BamHI and XhoI,
which introduced an in-frame hexahistadine tag at the N terminus
(His6-Gi2
N270D-pFastBacHta). Other Sf9 expression plasmids were de-
scribed previously (36, 37).
GPA1Q323L, GPA1N388D, GPA2N365D, and Gi2
N270D mutations were
introduced using QuikChange. The primer sequences are as follows:
5-TCGACGCTGGAGGCCTGCGTTCTGAACG-3 and 5-CGTTCAGA-
ACGCAGGCCTCCAGCGTCGA-3 for GPA1Q323L; 5-CGTTTATTTTG-
TTTTTAGATAAAATTGATTTGTTC-3 and 5-GAACAAATCAATTTT-
ATCTAAAAACAAAATAAACG-3 for GPA1N388D; 5-TCTGTCGTACT-
CTTTCTGGATAAAATCGACCTTTT TG-3 and 5-CAAAAAGGTCGA-
TTTTATCCAGAAAGAGTACGACAGA-3 for GPA2N365D; 5-TCCATC-
ATCCTCTTCCTCGACAAGAAGGACCTGTTTG-3 and 5-CAAACAG-
GTCCTTCTTGTCGAGGAAGAGGATGATGGA-3 for Gi2
N270D. Each
mutation was confirmed by sequencing analysis.
Expression of G (Ste4/Ste18) was under the control of the bidi-
rectional GAL1/10 promoter in pRS424-GAL-STE4/STE18. This
plasmid was constructed by combining a SalI-EcoRI digestion product
containing the GAL1/10 promoter and STE4 (from pL19, provided by
Malcolm Whiteway, University of Montreal) (38) with an EcoRI-SacI
digestion product of STE18 amplified by PCR using the primers 5-G-
GGAATTCTAGGATAGTAGCAATCGCA-3 and 5-GAGGCTCTACGT-
AGCAAG-3 and a SalI-SacI digestion product of plasmid pRS424.
Expression of STE2 or STE7 was achieved by PCR amplification and
subcloning into the pYES2.1/V5-His-TOPO (2 m, URA3, GAL1/10
promoter, CYC1 terminator; Invitrogen). Amplification primers used
were 5-CCCAAGCTTCCAGAATGTCTGATGCGGCTCCTTC-3 and 5-
CCCAAGCTTTAAATTATTATTATCTTCAGTC-3 for STE2; 5-GCAT-
CGGATCATATCTGTTT-3 and 5-GCTGGAAAAAGAAGAGACTA-3
for STE7. A stretch of double-stranded DNA encoding three tandem
repeats of the FLAG tag (sense, 5-GATTATAAAGATGACGATGACA-
AGGATTATAAAGATGACGATGACAAGGATTATAAAGATGACGAT-
GACAAG-3) in pYES2.1/V5-His-TOPO was digested with HindIII and
ligated to HindIII-digested STE2 that had been PCR-amplified using
the primers 5-CCCAAGCTTCCAGAATGTCTGATGCGGCTCCTTC-3
and 5-CCCAAGCTTTAAATTATTATTATCTTCAGTC-3, yielding
pYES-STE2-FLAG.
Expression of Gi2
ND in Insect Cells—A baculovirus encoding human
Gi2
N270D with an N-terminal hexahistidine tag was prepared and
amplified using plasmid his6-Gi2
N270D-pFastBacHta according to the
manufacturer’s instructions (Invitrogen). Four liters of Sf9 cells at a
density of 1.5  106 cells/ml were infected with the virus at a multi-
plicity of infection of 2 and harvested 48 h after infection by centrifu-
gation at 1,000  g for 15 min at 4 °C. All subsequent steps were carried
out at 4 °C. Cells were resuspended in 400 ml of ice-cold cell lysis buffer
(20 mM HEPES, pH 8, 100 mM NaCl, 2 mM MgCl2, 9.8 mM 2-mercapto-
ethanol, 0.01 mM GDP, 500 nM aprotinin, 10 M leupeptin, 200 M
phenylmethylsulfonyl fluoride, 1 nM pepstatin, 10 M L-1-tosylamido-2-
phenylethyl chloromethyl ketone) and lysed by passage through a pres-
surized Emulsiflux (Avestin, Ottawa, Canada). The lysate was centri-
fuged at 500  g for 15 min to remove intact cells and nuclei. The
cleared lysate was further centrifuged at 150,000  g for 35 min in an
ultracentrifuge (Beckman). The resulting supernatant fraction was
passed over an equilibrated 2.5-ml nickel-nitrilotriacetic acid (Ni-NTA)-
agarose resin (Qiagen) column at a flow rate of 2 ml/min, and the
flow-through was reapplied to the column. The column was washed
with 10 ml of high salt wash (cell lysis buffer  300 mM NaCl), and 10
ml of 10 mM imidizole in cell lysis buffer. His-Gi2
N270D was eluted with
10 ml of 150 mM imidazole in cell lysis buffer, diluted 1:4 in Buffer A (20
mM HEPES, pH 8, 2 mM MgCl2, 1 mM dithiothreitol, 0.5 mM EDTA, 0.01
mM GDP, 500 nM aprotinin, 10 M leupeptin, 200 M phenylmethylsul-
fonyl fluoride, 1 nM pepstatin, 10 M L-1-tosylamido-2-phenylethyl chlo-
romethyl ketone), and loaded onto an equilibrated 1-ml HiTrap Q-
Sepharose FPLC column (Amersham Biosciences) according to the
manufacturer’s recommendations. A linear gradient from 0 to 500 mM
NaCl (30 ml) was used to elute proteins bound to the column. Five
hundred microliter fractions were collected and immediately assayed
for [35S]GTPS binding and GTPase activity.
[35S]GTPS Binding Assay—[35S]GTPS binding assays were per-
formed in triplicate in conical polypropylene tubes (Sarstedt) in a 100-l
reaction volume. Fifty microliters of each sample was added to 50 l of
2 GTPS binding buffer (50 mM HEPES, pH 8, 4 mM MgCl2, 1 mM
EDTA, 5 M GTPS, 500,000 cpm/reaction [35S]GTPS) and incubated
in a 30 °C water bath for 60 min. Reactions were then transferred to ice
and diluted with 5 ml of ice-cold stop buffer (20 mM Tris-HCl, pH 8, 25
mM MgCl2, 120 mM NaCl). The diluted reactions were filtered over
pre-wetted 0.45-m type HA nitrocellulose filters (Millipore) using a
vacuum manifold and washed twice with 5 ml of stop buffer. The filters
were then added to scintillation vials with scintillant, and radioactivity
was determined using a scintillation counter.
GTPase Activity—Steady state GTPase assays were performed in
duplicate in conical polypropylene tubes in a 50-l reaction volume.
Twenty five microliters of each sample was added to 25 l of 2 GTPase
buffer (40 mM HEPES, pH 8, 100 mM NaCl, 4 mM MgCl2, 2 mM EDTA,
4 M GTP, 625,000 cpm/reaction [-32P]GTP) and incubated in a 30 °C
water bath for 30 min. To terminate the reaction, the tubes were moved
to an ice bath, and 950 l of suspended 5% activated charcoal (Sigma)
in 20 mM NaH2PO4 was added to each tube. The reaction tubes were
subjected to centrifugation at 3,000  g in a swinging bucket centrifuge
for 10 min to collect the charcoal pellet. Six hundred microliters of the
cleared supernatant were transferred to scintillation vials with scintil-
lation fluid for quantification of radioactivity.
Pheromone Signaling Assays—Two outcomes of pheromone signaling
were measured. The first was pheromone-dependent growth inhibition
(halo assay) (39). Briefly, 100 l of a saturated cell culture was mixed
with 2 ml of water and 2 ml of 1% (w/v) dissolved agar (55 °C) and
poured onto selective SCD or SCG agar plates. Synthetic -factor was
spotted onto sterile paper disks and placed on the nascent lawn. The
resulting zone of growth inhibition was recorded after 48 h.
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The second assay was pheromone-dependent reporter transcription
activity (39). In this method a pheromone-inducible promoter (FUS1)
drives expression of a reporter enzyme (-galactosidase) (39). A satu-
rated cell culture in selective SCD medium was diluted 1:200 in fresh
SCD medium, allowed to grow overnight, washed, and resuspended in
SCG medium to A600 nm 0.6. After 4 h the cells were aliquoted (90 l,
in triplicate) to 96-well plates containing 10 l of -factor and incubated
for 90 min at 30 °C. -Galactosidase activity was measured by adding
20 l of a freshly prepared solution of 83 M fluorescein di--D-galac-
topyranoside (Marker Gene Technologies Inc.), 137.5 mM PIPES, pH
7.2, 2.5% Triton X-100 and incubating at 37 °C until a bright yellow
color appeared. The reaction was stopped by the addition of 20 l of 1 M
Na2CO3, and the fluorescence activity was monitored using an excita-
tion of 485 nm and an emission of 530 nm.
Heat Shock Assay—A saturated cell culture in selective SCD medium
was diluted 1:20 into fresh SCD medium and incubated for 48 h. Cell
cultures were then transferred to glass tubes and placed in a 50 °C
water bath for 45 min. Heat-shocked (50 °C) and nonheat-shocked
(30 °C) cells were diluted and plated on selective SCG agar plates.
Surviving cell colonies were counted after 2–3 days (23).
Gpa1 and Gpa1N388D Expression Assay—To compare expression of
Gpa1 versus Gpa1N388D, protein concentration was examined in the
gpa1 deletion YGS5 strain and in the diploid YPH501 strain, which
normally does not express the receptor or G protein. To assess regula-
tion by pheromone, -factor (2.5 M) was added at A600 nm 0.6 and
incubation continued for an additional 2 h. Cells were grown to mid-log
phase in SCG (A600 nm 1.0), and cell growth was stopped by addition of
10 mM (final concentration) NaN3. Cells were harvested by centrifuga-
tion at 1,000  g for 10 min. Cells were washed once with 10 mM NaN3
and resuspended in phosphate-buffered saline, pH 7.3. Cells were then
lysed by vortexing with glass beads four times for 1 min each and then
centrifuged at 10,000  g for 30 s. The resulting supernatant was
collected and mixed with SDS-PAGE sample buffer (60 mM Tris-HCl,
pH 6.8, 10% glycerol, 14.4 mM 2-mercaptoethanol, 10 g/ml bromphenol
blue, 4% SDS) and heated at 100 °C for 10 min. The samples were
allowed to cool and subjected to immunoblotting analysis (see below).
To compare stability of Gpa1 and Gpa1N388D, cycloheximide was added
(10 g/ml final concentration) for various times prior to harvesting
the cells.
Co-purification of Gpa1 with G—YPH501 cells expressing receptor
(Ste2), G (Ste4/Ste18), and either G (Gpa1) or GND (Gpa1N388D)
fused to glutathione S-transferase (GST) or GST alone were grown in
selective SCG medium. All the following procedures were carried out at
4 °C. After termination of cell growth, 50 A600 nm units of cells were
resuspended in purification lysis buffer (40 mM triethanolamine, pH
7.2, 2 mM EDTA, 150 mM NaCl, 2 mM dithiothreitol, 0.2 mM 4-[2-
aminoethyl]benzenesulfonyl fluoride HCl, 15 g/ml leupeptin, 20 g/ml
pepstatin, 1 mM benzamidine, 10 g/ml aprotinin, 100 M glycerol
2-phosphate, 0.5 mM sodium orthovanadate). Cells were split into two
equal portions, and each portion was resuspended in 1 ml of lysis buffer
containing 3 mM MgCl2 and 10 M GDP (condition 1, “AlF4
”) or 3 mM
MgCl2, 10 M GDP, 30 M AlCl3, and 10 mM NaF (condition 2, “AlF4
”).
Cells were lysed by vortexing with glass beads four times for 1 min each.
The resultant lysates were harvested by centrifugation at 1,000  g for
10 min and solubilized by addition of Triton X-100 (1% final concentra-
tion) and rocking for 1 h. The samples were then centrifuged at 1,000 
g for 10 min, and the resulting supernatant was mixed with 100 l of a
30% slurry of glutathione-Sepharose 4B (Amersham Biosciences) in the
appropriate lysis buffer (condition 1 or condition 2) and incubated for
2 h. The glutathione-Sepharose 4B was centrifuged at 10,000  g for 10
min and washed three times with 1 ml of phosphate-buffered saline.
The bound proteins were eluted by heating at 100 °C in SDS-PAGE
sample buffer.
Co-immunoprecipitation of Receptor (Ste2) and Gpa1—YPH501 cells
expressing G (Ste4/Ste18), Gpa1, or Gpa1N388D and receptor (Ste2)
tagged or nontagged with the FLAG epitope were grown in selective
SCG medium to A600 nm 1.0. All the following procedures were con-
ducted at 4 °C. Twenty five A600 nm units of cells were resuspended in IP
lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Triton X-100,
5 mM EDTA, 10% glycerol, 100 g/ml phenylmethylsulfonyl fluoride, 1
mM dithiothreitol, 1 of protease inhibitor mixture (catalog number
1873580; Roche Applied Science)), followed by vortexing with glass
beads four times for 1 min each. Cell lysates were harvested by centrif-
ugation at 1,000  g for 10 min, and the supernatant was subjected to
FIG. 1. Nucleotide binding and
GTPase activity of purified Gi2
N270D.
Recombinant his6-Gi2
N270D was purified
from Sf9 cell lysates by Ni-NTA affinity
chromatography followed by ion exchange
chromatography, as described under “Exper-
imental Procedures.” A, His6-Gi2
N270D was
eluted from an ion exchange column using a
0–500 mM NaCl linear gradient. Purity was
assessed by Coomassie Blue staining of
12.5% acrylamide SDS-PAGE gels. Fraction
numbers are provided above each lane, and
the position of molecular weight standards
(kDa) are indicated on the left. B, elution
fractions were resolved by SDS-PAGE,
transferred to nitrocellulose, and probed
with anti-pentahistidine antibody to detect
the presence of his6-Gi2
N270D. Fraction
numbers are provided above each lane. C,
elution fractions were assayed for [35S]-
GTPS binding and GTPase activities. Open
bars, [35S]GTPS binding. Samples (in trip-
licate) of each fraction were incubated with
2.5 M [35S]GTPS for 60 min at 30 °C. The
reactions were filtered over nitrocellulose,
and the retained radioactivity was quanti-
tated by scintillation counting to determine
GTPS binding activity. Hatched bars,
GTPase activity. Samples (in duplicate) of
each eluate fraction were incubated with 2
M [32P]GTP for 30 min at 30 °C. Activated
charcoal was added to each reaction and col-
lected by centrifugation, and radioactivity in
the supernatant was quantitated by scintil-
lation counting to determine free phosphate.
Fraction numbers are indicated below each
bar. Error bars, mean  S.E. Note that a
wider range of fractions are included in B
and C than in A.
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1 h of rocking to liberate membrane-bound proteins. The samples were
then centrifuged at 10,000  g for 10 min, and the resulting superna-
tant was incubated with 40 l of a 50% slurry of EZviewTM Red anti-
FLAG M2 affinity gel (Sigma). After 2 h of gentle agitation, the gel was
centrifuged at 10,000  g for 30 s and washed three times with IP lysis
buffer. Elution of FLAG-tagged protein was achieved by incubating the
gel with 15 g of 3 FLAG peptide in 50 l of elution buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA) with gentle shaking for 30
min. Supernatant was harvested by centrifugation at 8,000  g for 30 s
and subjected to immunoblotting assay.
Immunoblot Detection—Protein samples in SDS-PAGE sample buffer
were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and
probed with antibodies against Gpa1 (1:1,000 dilution) (40), FLAG (1:
3,000; Sigma), GST (1:1,500; from Joan Steitz, Yale University), Ste4
(1:2,000; from Duane Jenness, University of Massachusetts), or Gi2
(1:2,500; Qiagen). Antibodies were detected using secondary antibodies
such as horseradish peroxidase-conjugate goat anti-mouse IgG or anti-
rabbit IgG (Bio-Rad). The signal was detected by the ECL system (Am-
ersham Biosciences) according to the manufacturer’s instructions.
RESULTS
GND Can Bind and Hydrolyze GTP—Gpa1N388D is a potent
inhibitor of pheromone signaling. Other investigators have
suggested that this mutation impairs GTPase function and
proposed that the inhibition of signaling might occur through
activation of a “desensitization effector” (28–30, 41). However,
the GTPase activity of the ND mutant has not been measured
in any system. A previous attempt to purify recombinant
Gpa1N388D from bacteria yielded a product unable to hydrolyze
GTP, but which was also unable to bind to GTP or G (28).
These findings suggest that the mutant protein is unstable and
loses activity during purification. As an alternative strategy we
attempted to purify the analogous mutant form of Gi2 ex-
pressed in insect cells. Gi is the closest mammalian homo-
logue to Gpa1; both proteins have nearly identical guanine
nucleotide binding pockets, and a direct comparison revealed
that they have very similar kinetic properties in vitro (27).
As shown in Fig. 1, we were able to purify small quantities of
the mutant protein from insect cells. We generated a baculovi-
rus encoding human Gi2
N270D fused at the N terminus to a
hexahistidine affinity tag (his6-Gi2
N270D). Sf9 cell infection
with the virus resulted in heterologous expression of the mu-
tant protein, although at significantly lower levels than that
observed following infection with a similar virus encoding wild-
type Gi2 (data not shown). Lysates were separated by high
speed centrifugation into particulate and soluble fractions, and
the soluble fraction was passed over an Ni-NTA affinity col-
umn. After extensive washing the his6-Gi2
N270D was eluted
with 150 mM imidazole. Fractions were then resolved by SDS-
PAGE and visualized by staining with Coomassie Blue as well
as by immunoblotting and detection with anti-pentahistidine
antibodies. Both detection methods revealed a single promi-
nent band migrating at 40.5 kDa, which is the predicted mo-
lecular mass of his6-Gi2
N270D (data not shown).
To further purify his6-Gi2
N270D, the 150 mM imidazole elu-
ate was diluted and passed over an anion exchange resin (Hi-
Trap Q-Sepharose). The column was washed, and bound pro-
teins were eluted with a linear salt gradient. Elution fractions
were again analyzed by protein staining and immunoblotting
as described above. As shown in Fig. 1A, his6-Gi2
N270D repre-
sented greater than 50% of the total protein in fractions with
significant [35S]GTPS binding activity (see below). his6-
FIG. 2. Gpa1N388D inhibits pheromone-dependent growth ar-
rest. To measure pheromone-dependent growth arrest, wild-type cells
(strain BY4741) were transformed with wild-type GPA1 or GPA1N388D
expressed from an attenuated GAL1/10 promoter having 1 (GALL) or
20% (GALH) of wild-type activity. Cells were plated onto medium con-
taining either galactose (to induce expression) or glucose (to repress
expression) and exposed to filter disks spotted with -factor pheromone
(clockwise from top left, 75, 25, and 8 g). The resulting zone of growth
inhibition was documented after 2–3 days.
FIG. 3. Gpa1N388D inhibits pheromone-induced transcription.
To measure pheromone-dependent transcription, wild-type cells (strain
BY4741) were co-transformed with a reporter plasmid containing the
pheromone-responsive FUS1 promoter fused to lacZ and a second plas-
mid containing GPA1N388D (A), GPA2N365D (B), or no insert (Vector, A
and B) expressed from either the GALL or GALH promoter. Cells were
grown in the presence of galactose and analyzed for -galactosidase
activity following treatment with the indicated concentrations of -fac-
tor. -Galactosidase activity units are arbitrary. Each point is an aver-
age of three measurements, and the data shown are representative of
three independent experiments. Error bars, S.E.
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Gi2
N270D immunoreactivity did not elute as a discrete species
but rather in two broad peaks over a wide range of NaCl
concentrations (Fig. 1B). These results suggest that the protein
was not monodisperse, consistent with our observations that
protein solubility and GTPS binding activity of his6-Gi2
N270D
decline rapidly (see below).
The Q-Sepharose eluate was assayed for [35S]GTPS binding
and GTPase activities. As shown in Fig. 1C, substantially more
[35S]GTPS binding and GTPase activity was observed in the
first peak (fractions 32–36) than in the second peak, suggesting
that the his6-Gi2
N270D present in the later fractions was inac-
tive. Even in this early peak the active form of the protein
(determined by GTPS binding) was 15% of the estimated
total concentration of Gi2
N270D (determined by protein stain-
ing). Wild-type his-Gi2 purified under the same conditions
eluted as a single discrete peak at 200 mM NaCl, and these
fractions exhibited nearly stoichiometric [35S]GTPS binding
(data not shown).
Significant loss of [35S]GTPS binding activity of Gi2
N270D
occurred as a function of time and temperature. For this reason
all purification steps were carried out at 4 °C, and all assays of
[35S]GTPS binding and GTPase activities were performed
within 10 h of cell lysis. Despite these precautions, it appeared
that much of the protein was inactive, further suggesting that
the protein is unstable (data not shown).
Finally, we observed that co-expression with G1 and G2
increased the proportion of Gi2
N270D associated with the mem-
brane fraction, suggesting that the mutant protein interacts
with G dimers and is recruited to the membrane by this
interaction (data not shown). We have also co-expressed un-
tagged Gi2
N270D and pentahistidine-tagged G2 with G1 and
purified the heterotrimeric complex by Ni-NTA and ion ex-
change chromatography. We found that Gi2
N270D co-eluted
with his6-G in this procedure, further suggesting that the
mutant associates with G (data not shown).
Gpa1N388D Is a Receptor- and G Subtype-selective Domi-
nant-negative Mutant—The data presented in Fig. 1 indicate
that GND binds and hydrolyzes GTP normally. This makes it
unlikely that Gpa1N388D functions by activating any effector
protein, because effectors recognize only the GTP-bound form
of G. We therefore considered whether the mutant functions
as a dominant negative. Dominant-negative mutants will,
when overexpressed, inhibit the function of the endogenous
wild-type protein (14). In this scenario, the Gpa1N388D pheno-
type could result from interference with receptor-G protein
coupling, from inhibition of G protein subunit dissociation, or
from both.
As an initial test of the model we asked whether Gpa1N388D
specifically inhibits the signaling activity of the pheromone
FIG. 4. Gpa2N365D inhibits recovery from heat shock. Wild-type
cells (strain YPH499) were transformed with a plasmid containing no
insert (Vector), wild-type GPA1, wild-type GPA2, GPA1N388D, or
GPA2N365D under the control of the GALH promoter. Cells in liquid
medium were placed in either a 50 °C water bath for 45 min (A) or
maintained at the normal growth temperature of 30 °C (B) and then
plated onto solid medium. Colonies were counted after 2–3 days. Heat
shock recovery was expressed as the relative survival rate of each
transformed strain and expressed relative to the vector control group
(defined as 100%). Each value is an average of three measurements,
and the data shown are representative of four independent experi-
ments. Error bars, S.E.
FIG. 5. Signal inhibition by Gpa1N388D requires receptor cou-
pling activity. To determine whether coupling to receptors is required
for Gpa1N388D activity, wild-type cells (strain BY4741) were trans-
formed with plasmid pAD4M containing GPA1N388D-GST, GPA1-GST,
or GST alone. Fusion to GST preserves G binding but blocks activa-
tion by receptors, as discussed above. A, cells were plated onto selective
medium and exposed to disks spotted with -factor pheromone (clock-
wise from top, 75, 25, 8, and 0 g). The resulting zone of growth
inhibition was documented after 2–3 days. B, total lysates were pre-
pared from the cells used in A, resolved by 7.5% SDS-PAGE, and
subjected to immunoblotting with anti-GST antibodies (Ab). Arrows
indicate full-length protein specifically detected by the antibody. Other
bands are presumed to be degradation products.
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receptor Ste2. Two distinct GPCR signaling pathways exist in
yeast. In haploid cells, the primary function of Ste2 is to mod-
ulate the activity of Gpa1 (G) and the Ste4/Ste18 dimer (G)
(22). Activation of this pathway leads to growth arrest and
mating. Although less well characterized, a putative glucose
receptor Gpr1 modulates the activity of Gpa2 (G), Gpb1 or
Gpb2 (G-like proteins), and Gpg1 (G). Activity of this path-
way allows the cell to adapt to cell stress (42).
We first compared pheromone signaling in wild-type cells
that express Gpa1N388D or the analogous mutant form of Gpa2,
Gpa2N365D. Both G mutants were expressed using the atten-
uated galactose-inducible promoters, GALH (20% of wild-type
activity) and GALL (1% of wild-type activity). Two outcomes of
pheromone signaling were measured. The first was pheromone-
mediated cell growth arrest (halo assay). Pheromone spotted
onto a filter disk produces a zone of growth arrest the size of
which correlates with pheromone sensitivity. As shown in Fig.
2, modest overexpression of Gpa1N388D inhibited the response
to pheromone, as described previously (30). Inhibition was de-
pendent on the expression level of Gpa1N388D as the GALH
promoter conferred more effective inhibition (Fig. 2, bottom
panel) than GALL (top panel). Inhibition was absent when
expression was repressed by growth in glucose. Expression of
wild-type Gpa1, wild-type Gpa2, or Gpa2N365D also did not
affect the halo response (Fig. 2 and data not shown).
We then examined the effects of the ND mutation by using a
pheromone-dependent gene transcription assay. In this
method, induction of a pheromone-inducible promoter (from
FUS1) leads to increased expression of a reporter enzyme (-
galactosidase). As shown in Fig. 3A, expression of Gpa1N388D
caused a significant reduction in -galactosidase activity, and
the effect was again dependent on the level of mutant expres-
sion (GALH was more effective than GALL). Inhibition was
observed only when expression of the mutant was induced by
galactose (data not shown). Expression of wild-type Gpa1, wild-
type Gpa2, or Gpa2N365D had no effect on signaling (Fig. 3B,
and data not shown). Thus, the two functional assays are in
agreement and together show that pheromone signaling is
diminished upon overexpression of Gpa1N388D but not
Gpa2N365D.
We then characterized the effect of the ND mutation on
signaling by Gpa2. No reporter-transcription assay is available
that is selective for signaling by Gpa2 (the widely used FLO11
reporter is also induced by pheromone, data not shown). How-
ever, Gpa2 was shown previously (23, 25) to regulate survival
after heat shock. Thus, we investigated whether Gpa2N365D
would likewise enhance heat shock sensitivity. As shown in
Fig. 4, Gpa2N365D significantly reduced the survival rate of
cells grown at 50 °C for 45 min (Fig. 4A). In contrast, wild-type
Gpa2, Gpa1, or Gpa1N388D exhibited no effect on heat shock
sensitivity. Likewise, no difference was observed among any of
the tested strains maintained at 30 °C (Fig. 4B). Taken to-
gether, these data indicate that Gpa2N365D (but not Gpa1N388D)
acts in the Gpr1-Gpa2 pathway, whereas Gpa1N388D (but not
Gpa2N365D) diminishes Ste2-Gpa1-mediated pheromone sig-
naling. Stated differently, GND functions as a receptor-selec-
tive dominant-negative mutant.
Receptor Coupling Is Required for Gpa1N388D Dominant-neg-
ative Activity—The data above indicate that Gpa1N388D specif-
ically regulates Ste2 activity. This inhibitory effect could be due
to direct binding to the receptor, binding to G, or both. To
determine whether receptor coupling is required, we tested the
activity of Gpa1N388D fused at its C terminus to glutathione
S-transferase. The C-terminal region of G is required for
coupling to receptor but not for binding to G. We have shown
previously (34) that Gpa1-GST blocks receptor coupling but
preserves binding to guanine nucleotides and to G. As shown
in Fig. 5, the Gpa1N388D-GST fusion had no effect on the
growth arrest response. Expression of GST alone or wild-type
Gpa1-GST was also without effect in this assay (Fig. 5A).
Equal expression of each protein was confirmed by immuno-
blotting (Fig. 5B). These data indicate that the dominant-
negative activity of Gpa1N388D requires direct coupling to its
receptor.
Dominant-negative Activity of Gpa1N388D Depends on Recep-
tor Activation—Gpa1N388D evidently couples to its receptor
(Ste2), yet appears unable to undergo receptor activation. If
Gpa1N388D and the receptor indeed form an unproductive com-
plex, it remains unclear why any response to pheromone occurs
at least initially. One possibility is that Gpa1N388D is not nor-
mally associated with the receptor but is recruited in response
to prolonged pheromone stimulation. In contrast, any wild-type
Gpa1 normally associated with the receptor would be displaced
upon pheromone stimulation, allowing Gpa1N388D to bind and
thereby prevent further activation of wild-type Gpa1.
To test this aspect of the model, Gpa1N388D was expressed in
the absence of wild-type Gpa1 (i.e. a gpa1 mutant strain).
Cells lacking GPA1 are normally not viable due to constitutive
release of G leading to cell division arrest (43, 44). However,
FIG. 6. Pheromone-dependent inhibition of constitutive sig-
naling by Gpa1N388D in a gpa1 mutant strain. A, gpa1 ste7
mutant strain was transformed with plasmids containing STE7 under
the control of the GAL1/10 promoter and either wild-type GPA1 or
GPA1N388D under the control of the GALH promoter. Cells were plated
onto galactose-containing medium and exposed to -factor pheromone
(counter-clockwise from top, 75, 25, 8, and 0 g). The resulting zone of
pheromone-dependent cell growth was recorded after 2 days. B, the
same strain was transformed with plasmids containing STE7 (GAL1/10
promoter), the FUS1-lacZ reporter, and either GPA1N388D (GALH pro-
moter) or wild-type GPA1 regulated by its native promoter (pRS315-
GPA1). Each point is an average of three measurements, and the data
shown are representative of three independent experiments. Error
bars, S.E.
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the cells used here also do not express the downstream kinase
gene STE7 and are viable. Thus, signaling can be monitored by
growth arrest and reporter transcription assays following in-
duction of STE7 expression from a plasmid.
As predicted by the model, Gpa1N388D blocked cell division
arrest in pheromone-treated cells (those nearest the source of
pheromone) (Fig. 6A) (45). Cells grew poorly at the perimeter of
the halo, where pheromone concentrations are reduced (Fig.
6A). Cells expressing wild-type Gpa1 exhibited a more typical
growth arrest phenotype. Cells closest to pheromone under-
went cell division arrest, whereas those further away continued
to grow. This pattern of signaling supports the model that
Gpa1N388D can inhibit signaling, but only upon receptor acti-
vation. This is in contrast to wild-type Gpa1, which promotes
signaling upon receptor activation.
The growth arrest data suggest that Gpa1N388D can form a
stable complex with pheromone-occupied receptor and G.
Alternatively, Gpa1N388D could subserve a role in cell division
cycling independent of its ability to bind G. To rule out this
possibility we measured the transcription induction response
in the same cells. Transcription induction coincides with, but
does not require, cell division arrest (46). Whereas wild-type
Gpa1 conferred dose-dependent activation of the transcription
reporter (Fig. 3), Gpa1N388D (in the absence of wild-type pro-
tein) produced a high basal transcription activity and a dose-
dependent inhibition of the response (Fig. 6B). These data
mirror that seen in the growth arrest assay, and further sug-
gest that Gpa1N388D binds to pheromone-activated receptor
and G. However, rather than leading to activation, the mu-
tant appears to remain stably bound to receptor and G.
Pheromone Stimulation Increases Gpa1N388D Stability and
Expression—The above results suggest that pheromone trig-
gers the association of Gpa1N388D with G and receptor. Thus,
we investigated the mechanism by which pheromone treatment
can unmask the apparent ability of Gpa1N388D to sequester
G. One possibility is that pheromone is required for stable
expression of Gpa1N388D (47). Indeed, purification of Gi2
N270D
or Gpa1N388D yielded protein that was unstable in vitro (28).
Thus we considered whether Gpa1N388D is also unstable
in vivo.
To determine whether Gpa1N388D is unstable, we monitored
its rate of loss in cells following treatment with the protein
synthesis inhibitor cycloheximide. As shown in Fig. 7A, over-
expressed wild-type Gpa1 protein was quite stable, with almost
no change after a 90-min treatment with cycloheximide. In
contrast, Gpa1N388D was expressed at much lower levels, and
expression was undetectable after only 30 min of translation
inhibition (Fig. 7A). These data indicate that the mutant
is unstable.
To determine whether stability is influenced by receptor
activation, the same cells were treated with pheromone, and
Gpa1N388D expression was again measured by immunoblotting.
As shown in Fig. 7B, addition of pheromone resulted in ele-
vated expression of Gpa1N388D but had no effect on the already
high levels of wild-type Gpa1. These data suggest that phero-
mone promotes more stable expression of Gpa1N388D. The ele-
vated expression might allow the mutant protein to associate
with G and thereby inactivate the signal.
FIG. 7. Pheromone-dependent ex-
pression of Gpa1N388D. A, to measure
Gpa1N388D expression, a gpa1 mutant
(strain YGS5) was transformed with a
plasmid containing either no insert (Vec),
wild-type GPA1, or GPA1N388D under the
control of the GALH promoter. Cells were
grown to mid-log phase in galactose me-
dium and then treated with the protein
synthesis inhibitor cycloheximide (CHX)
for the indicated times. Whole cell lysates
were resolved by 7.5% SDS-PAGE and sub-
jected to immunoblotting with anti-Gpa1
antibodies. B, the same cells as in A were
grown for 18 h in the absence or presence of
2.5 M -factor, as indicated (o/n -MF).
Another addition of -factor was made 2 h
prior to collecting the cells, as indicated
(-MF). Whole cell lysates were resolved by
7.5% SDS-PAGE and subjected to immuno-
blotting with anti-Gpa1 antibodies (Ab).
Arrows indicate protein specifically de-
tected by the antibody (Ab). Data are rep-
resentative of four experiments.
FIG. 8. Receptor- and G-depend-
ent expression of Gpa1N388D. To deter-
mine the relative contribution of receptor
and G to stable Gpa1N388D expression,
wild-type diploid cells (strain YPH501)
were transformed with plasmids contain-
ing no insert (Vec), wild-type GPA1, or
GPA1N388D, alone or in combination with
plasmids that express receptor (STE2),
G (STE4/18), or both, as indicated.
Whole cell lysates were resolved by 7.5%
SDS-PAGE and subjected to immunoblot-
ting with anti-Gpa1 antibodies (Ab). The
arrows indicate the protein specifically
detected by the Gpa1 antibody. Data are
representative of four experiments.
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In Vivo Reconstitution of Receptor, G, and Gpa1N388D—
The data presented above indicate that pheromone-occupied
receptor slows the degradation of Gpa1N388D. Therefore, we
asked whether binding to G also contributes to stable ex-
pression of the mutant protein. These experiments were con-
ducted in diploid cells, which normally lack the receptor and G
protein subunits. Through heterologous expression of each
component, alone or in combination, we determined the rela-
tive contribution of each to stabilized expression of Gpa1N388D.
As shown in Fig. 8 (top panel), Gpa1 and Gpa1N388D proteins
were barely detectable when expressed alone. The abundance
of both the mutant and wild-type protein was enhanced by
co-expression of the receptor and was further enhanced by
co-expression of both the receptor and G (bottom panel).
Most surprising, pheromone treatment in this case did not
appear to affect the expression of either the wild-type or mu-
tant protein. This could be due to overexpression of the signal-
ing proteins, which might dampen signaling efficiency or re-
flect the absence in diploids of another required signaling
component such as the haploid-specific proteins Ste5, Far1,
Sst2, or Fus3. Nevertheless, these results support our hypoth-
esis that receptor helps to stabilize the expression of
Gpa1N388D. These data also reveal a contribution of G to
G stability.
GTPase Activity Is Not Required for Gpa1N388D Dominant-
negative Activity—The intrinsic GTPase activity of the G sub-
unit is normally required for G protein subunits to reassociate
and for signaling to cease (48). Agonist-occupied receptors func-
tion by stabilizing the guanine nucleotide-free state, so stable
formation of a receptor-G protein complex should not require
the ability to catalyze GTP hydrolysis. To test this aspect of the
model, we introduced a second mutation (Q323L) that is incom-
patible with GTPase activity (27). The effect of the Q323L/
N388D double mutant was compared with N388D alone, using
both the cell growth inhibition assay and the transcription
activation assay. As shown in Fig. 9, Gpa1Q323L/N388D and
Gpa1N388D produced a similar response in both assays. These
data demonstrate that GTP hydrolysis is not required for
Gpa1N388D to inhibit pheromone signaling, in agreement with
our model.
Gpa1N388D Binds G (Ste4/18)—Typically, G subunits
bind to G in the presence of GDP but not GTP (48). Our
model predicts that Gpa1N388D binds the receptor, G and
guanine nucleotides but fails to dissociate from G following
receptor activation. One possibility is that Gpa1N388D is locked
in the inactive conformation and therefore does not undergo the
conformational changes needed to liberate G. Alternatively,
Gpa1N388D might couple to the receptor but is unable to un-
dergo receptor-dependent guanine nucleotide exchange re-
quired for subunit dissociation. To rule out the first of these two
possibilities, we investigated whether Gpa1N388D undergoes
the conformational change necessary for G dissociation.
Gpa1N388D and Gpa1 were fused to GST, expressed, and puri-
fied by glutathione-Sepharose affinity chromatography. As
shown in Fig. 10, Ste4/Ste18 (G) bound to either Gpa1-GST
or Gpa1N388D-GST, when purified in the presence of GDP.
Addition of AlF4
 converts G to the active conformation, and
this treatment led to dissociation of Ste4/Ste18 from either
protein; indeed, the binding properties of Gpa1N388D-GST were
almost identical to that of wild-type Gpa1-GST (Fig. 10). These
data indicate that Gpa1N388D retains the ability to undergo a
conformational change leading to G release. These data also
support our model that Gpa1N388D forms a stable complex with
G as well as receptor but does not liberate G from receptor
after pheromone stimulation, and as a consequence inhibits
pheromone signaling.
Pheromone Promotes Stable Coupling of Gpa1N388D to Recep-
tor—The previous experiments demonstrated that pheromone
promotes interaction of the receptor with Gpa1N388D and G.
G protein subunit binding is reversible but does not occur even
with pheromone stimulation. These results suggest that pher-
omone promotes coupling but not activation of Gpa1N388D. As a
final test of this hypothesis, we investigated whether
Gpa1N388D is recruited to the receptor in response to phero-
mone binding. Our approach was to immunopurify receptor
and track the interaction of Gpa1N388D before and after pher-
omone stimulation. Diploids were used because (in contrast to
haploid cells) they express similar levels of Gpa1 and
Gpa1N388D, thereby allowing a more valid comparison of bind-
ing of wild-type and mutant proteins.
The receptor was fused to a triple-FLAG epitope tag (Ste2-
FLAG) and co-expressed with either wild-type Gpa1 or
Gpa1N388D as well as Ste4/18. The receptor and any associated
G protein were then immunoprecipitated and resolved by gel
electrophoresis and immunoblotting. As shown in Fig. 11,
treatment with pheromone caused diminished binding of recep-
tor to wild-type Gpa1. In contrast, pheromone treatment en-
hanced the interaction of receptor with Gpa1N388D. Even with-
out pheromone treatment, the receptor appeared to have a
higher affinity for Gpa1N388D than wild-type Gpa1 (Fig. 11).
These data indicate that receptor activation by pheromone not
only stabilizes Gpa1N388D expression but also actively pro-
motes assembly of a receptor-Gpa1N388D-G complex. This
complex would preclude access of endogenous wild-type Gpa1
and therefore inhibit pheromone signal propagation in a dom-
inant-negative manner.
DISCUSSION
We have characterized a novel mutant (designated GND)
and found that it acts as a potent dominant-negative inhibitor
FIG. 9. GTPase activity is not required for Gpa1N388D function.
To determine whether GTP hydrolase activity is required for Gpa1N388D
function, a second mutation (Q323L) was introduced into GPA1N388D.
The gpa1 ste7 mutant strain was transformed with a plasmid con-
taining either GPA1N388D or GPA1N388D/Q323L under the control of the
GALH promoter and analyzed by using the growth inhibition assay
(-factor pheromone, counter-clockwise from top, 75, 25, and 8 g) (A)
and the transcription activation assay (B) as described above. Each
point is an average of three measurements, and the data shown are
representative of three independent experiments. Error bars, S.E.
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of receptor coupling to G proteins. We have shown that the
GND mutant binds and hydrolyzes GTP, binds G in a gua-
nine nucleotide-dependent manner, and binds receptor in an
agonist-dependent manner. We have also demonstrated that
the mutant is poorly expressed and rapidly degraded but ex-
pression is elevated by prolonged treatment with agonist. We
conclude that GND binds stably to the activated form of the
receptor and thereby prevents activation of endogenous wild-
type G protein.
Dominant-negative mutants have long been used to study a
variety of signaling proteins, most notably monomeric G pro-
teins such as Ras (49). At least three dominant-negative Ras
mutants have been identified (50–52). Extensive biochemical
analysis of the most widely used mutant, RasN17 (Ser-17 3
Asn mutation), revealed that it competes with normal Ras for
binding to guanine nucleotide exchange factors. More specifi-
cally, the mutant assumes an unactivable “dead-end” complex
with the exchange factor, thereby preventing it from binding to
the endogenous wild-type protein. This mechanism of action is
analogous to the one proposed here, in which Gpa1N388D is
thought to act by competing with normal Gpa1 for binding to
the receptor, thereby preventing activation of the pathway.
Although less widely used, dominant-negative mutations of
heterotrimeric G proteins have also been described. The earli-
est report was from Osawa and Johnson (15), who showed that
Gs
G226T could partially inhibit -adrenergic receptor-pro-
moted stimulation of cAMP synthesis. Simon and co-workers
(16, 53) described two other dominant-negative mutants,
Go
S47C and Gi
S48C, and showed that these mutants lack GTP
binding activity but retain G binding function. Another dom-
inant-negative Gs mutant was constructed using multiple
substitutions (17) including A366S, which decreases affinity for
GDP and causes the protein to spend more time in the empty
state (54), as well as G226A and E268A, two substitutions that
impair binding to GTP and the conformational changes re-
quired for dissociation of G (55, 56). More recently, Berlot
and co-workers (57, 58) have described a dominant-negative
Gs mutant that combines G226A and A366S with multiple
FIG. 10. G binds preferentially to
Gpa1N388D in the GDP-bound confor-
mation. To determine whether Gpa1N388D
binds to G in a guanine nucleotide-de-
pendent manner, diploid cells (strain
YPH501) were transformed with plasmids
containing STE2 (receptor), STE4/18
(G), and either wild-type GPA1-GST,
GPA1N388D-GST, or GST alone. The cells
were disrupted in the presence of GDP ()
or GDP and AlF4
 (), as indicated. Deter-
gent-solubilized lysates were then immobi-
lized on glutathione-Sepharose, washed,
and eluted with SDS-PAGE sample buffer.
Samples of total cell lysates (Applied) and
retained proteins (Bound) were resolved by
10% SDS-PAGE and subjected to immuno-
blotting with antibodies (Ab) against GST
or Ste4, as indicated. Data shown are rep-
resentative of three independent experi-
ments. Arrows indicate proteins specifi-
cally detected by the indicated antibodies.
FIG. 11. Pheromone-dependent
complex formation of Gpa1N388D and
receptor. To determine whether
Gpa1N388D forms a stable complex with
the receptor, diploid cells (strain YPH501)
were transformed with plasmids contain-
ing either tagged or untagged STE2,
STE4/18 (G), and either wild-type or
mutant GPA1 and then treated with 2.5
M -factor (-MF), as indicated. Deter-
gent-solubilized cell lysates were immu-
noprecipitated with anti-FLAG antibod-
ies. Samples of total cell lysates (Applied)
and purified proteins (IP) were resolved
by 7.5% SDS-PAGE and subjected to im-
munoblotting with antibodies that detect
Ste2 (FLAG Ab) and Gpa1. Data shown
are representative of three independent
experiments. Arrows indicate the proteins
specifically detected by the indicated
antibodies.
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substitutions in the 3 5 loop region that increase receptor
affinity, decrease receptor-mediated activation, and impair ac-
tivation of adenylyl cyclase. Expression of this mutant at close
to wild-type levels blocked signaling from the luteinizing hor-
mone receptor to Gs by up to 97% (21).
Perhaps the best characterized dominant-negative G mu-
tants are variants of Go, G11, and G16 that were engineered
to bind xanthine nucleotides instead of guanine nucleotides.
Xanthine monophosphate is an intermediate in the biosynthe-
sis of guanosine monophosphate. However, the cellular abun-
dance of xanthine diphosphate and xanthine triphosphate is
negligible, so the xanthine nucleotide-binding G proteins re-
main in the empty (nucleotide-free) state. Because it is the
nucleotide-free form of G that has highest affinity for agonist-
bound receptors, stable association with the mutant G protein
makes the receptor unavailable to activate the endogenous
wild-type G protein (18–20).
Gpa1N388D was originally reported to have no activity based
on its inability to rescue a gpa1 mutant (41) but was later
shown to promote recovery from pheromone-induced growth
arrest (30). Thus, Gpa1N388D was long known to have proper-
ties of a dominant-negative mutant, but not recognized as such
in part because of the earlier conclusion that Gpa1N388D is
incapable of binding to G. The evidence for lack of G
binding, albeit negative, is as follows: (i) Gpa1N388D failed to
prevent constitutive signaling in a cell lacking the GPA1 gene
(30, 41); (ii) Gpa1N388D displayed no binding to Ste4 in the
two-hybrid assay (30); and (iii) Gpa1N388D did not (in purified
recombinant form) bind to immobilized G (28). In contrast,
we have shown that G associates in a guanine-nucleotide-
dependent manner with both Gi2
N270D and Gpa1N388D. We
believe that earlier failures to detect binding stem from the
poor stability and poor expression of the mutant protein.
The mechanism of Gpa1N388D also was obscured by the long
held supposition (which was never demonstrated) that
Gpa1N388D lacks GTPase activity. Based on this assumption,
Stone and co-workers (28–30) proposed that Gpa1N388D is an
“activating” mutation that promotes recovery from growth ar-
rest via a desensitization effector. However, their model did not
account for the requirement for pheromone, which simulta-
neously requires binding of the receptor to all three subunits of
the G protein. Their model is also inconsistent with our obser-
vation that Gpa1Q323L (demonstrated previously to bind but
not hydrolyze GTP) has a phenotype opposite to that exhibited
by Gpa1N388D (10, 13). This prompted us to revisit the question
and test directly whether GTPase activity is affected. We found
that the protein is highly unstable in vitro but is nevertheless
able to bind and hydrolyze GTP. Based on our data, we propose
that Gpa1N388D is rapidly degraded but forms a more stable
complex with agonist-bound receptor and G. This complex
cannot be activated and therefore precludes further signaling
via the endogenous G or G. It is worth emphasizing that,
whereas the behavior of G dominant-negative mutants has
often been ascribed to stable association with the receptor, this
is the first time such an association has been documented.
Asn-388 lies within the conserved “Asn-Lys-X-Asp” sequence
that links the 5 strand and the 4 helix of all G protein 
subunits (59). All three conserved residues are present in Ras
and bacterial elongation factor Tu as well as in heterotrimeric
G proteins. In the available crystal structures Asn and Asp
form hydrogen bonds with the guanine ring of the nucleotide,
whereas the Lys methylene group provides a hydrophobic sur-
face that lies over the purine ring (59). Mutational substitution
of the Asp is sufficient to switch the nucleotide binding speci-
ficity from guanine to xanthosine in G (as discussed above) as
well as in Ras (60) and elongation factor Tu (61). Thus one
possibility is that substitution of the Asn relaxes nucleotide
binding specificity or affinity sufficiently to diminish activation
of the G protein by receptors. However, until a crystal structure
of a receptor and G protein heterotrimer becomes available, the
structural basis for the dominant-negative behavior will re-
main obscure.
Finally, distinct G proteins trigger a wide variety of signal
responses. In some instances, a single G protein activates mul-
tiple effectors. Conversely, multiple G proteins activate a com-
mon effector. By disrupting the activity of cognate activators or
effectors, dominant-negative G proteins could be used to iden-
tify upstream and downstream signaling components, regard-
less of how signaling specificity is achieved. If specificity de-
pends on intrinsic differences in receptor or effector binding,
the dominant-negative mutant should exhibit a similar binding
specificity and therefore as a consequence selectively block that
interaction. If a G protein has broad specificity for receptors but
is restricted in its activity through subcellular compartmental-
ization, the dominant-negative version of that protein should
have a similar subcellular distribution and would therefore
leave other signaling pathways unaffected.
G protein-coupled receptors clearly play an important role in
cellular physiology. Our ability to understand (and modulate)
receptor signaling has been hampered by a lack of pathway-
specific inhibitors, particularly inhibitors that act downstream
of receptors. In this regard, dominant-negative G proteins hold
tremendous promise for understanding how signaling net-
works are organized. Given that Asn-388 in Gpa1 is faithfully
conserved in all G proteins, comparable inhibitory mutants
should have a similar function in other G protein subtypes.
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